Novo Nordisk A/S
NONOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,755,596 | $3,110,420 | $2,147,852 | $1,667,096 |
| - Cash | $15,655 | $14,392 | $12,653 | $10,720 |
| + Debt | $102,787 | $27,006 | $25,784 | $26,645 |
| Enterprise Value | $2,842,728 | $3,123,034 | $2,160,983 | $1,683,021 |
| Revenue | $290,403 | $232,261 | $176,954 | $140,800 |
| % Growth | 25% | 31.3% | 25.7% | – |
| Gross Profit | $245,881 | $196,496 | $148,506 | $117,142 |
| % Margin | 84.7% | 84.6% | 83.9% | 83.2% |
| EBITDA | $137,376 | $111,041 | $76,802 | $64,826 |
| % Margin | 47.3% | 47.8% | 43.4% | 46% |
| Net Income | $100,988 | $83,683 | $55,525 | $47,757 |
| % Margin | 34.8% | 36% | 31.4% | 33.9% |
| EPS Diluted | 22.64 | 9.31 | 12.22 | 10.37 |
| % Growth | 143.2% | -23.8% | 17.8% | – |
| Operating Cash Flow | $120,968 | $108,908 | $78,887 | $55,000 |
| Capital Expenditures | -$51,309 | -$38,896 | -$14,753 | -$7,385 |
| Free Cash Flow | $69,659 | $70,012 | $64,134 | $47,615 |